A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

on March 1, 2024. (AP Photo/Amanda Andrade-Rhoades, File) More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands if they ...

Amy Schumer has opened up about the 'red flag' side effects she experienced while taking Ozempic, after she prompted other celebrities to 'be real' about their experiences. The comedian has been very ...

The U.S. Food and Drug Administration (FDA) has officially approved Ozempic to help reduce the risk of serious kidney complications in people with type 2 diabetes and chronic kidney disease. Type 2 ...

Amy Schumer has opened up about her experience using the popular Type 2 diabetes drug Ozempic, which also doubles as a weight loss drug. The actress revealed that being on the medication, along with ...

This approval, along with its existing indications for adults with type 2 diabetes to improve glycemic control and to reduce the risk of major cardiovascular events in adults also with known heart ...

LOS ANGELES, CALIFORNIA: Amy Schumer has revealed why she stopped using Ozempic, the Type 2 diabetes medication widely used for weight loss. Despite shedding 30 pounds, the comedian, 43, described her ...

establishes Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg as the most broadly indicated glucagon-like peptide-1 receptor agonist (GLP-1 RA) in its class,” the release noted. In 2020 ...

The FDA approval is based on results from the FLOW phase 3b kidney outcomes trial investigating the effects of once-weekly Ozempic injection on major kidney and cardiovascular outcomes in adults with ...

The “Trainwreck” star, 43, told Stern, 71, that she sees Ozempic and other GLP-1 drugs as “red flags ... Schumer came clean about her Ozempic use on “Watch What Happens Live with ...